NEW YORK (360Dx) – As Integrated Diagnostics prepares to launch its second-generation Xpresys Lung test, a study published this month in Chest finds the assay can rule out lung nodules as likely benign with a negative predictive value of 98 percent.
NEW YORK (360Dx) – As Integrated Diagnostics prepares to launch its second-generation Xpresys Lung test, a study published this month in Chest finds the assay can rule out lung nodules as likely benign with a negative predictive value of 98 percent.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.